Alzheimer’s disease: A matter of blood–brain barrier dysfunction?

Axel Montagne
2017-11-23

The blood–brain barrier (BBB) keeps neurotoxic plasma-derived components, cells, and pathogens out of the brain. An early BBB breakdown and/or dysfunction have been shown in Alzheimer’s disease (AD) before dementia, neurodegeneration and/or brain atrophy occur. However, the role of BBB breakdown in neurodegenerative disorders is still not fully understood. Here, we examine BBB breakdown in animal models frequently used to study the pathophysiology of AD, including transgenic mice expressing human amyloid-β precursor protein, presenilin 1, and tau mutations, and apolipoprotein E, the strongest genetic risk factor for AD. We discuss the role of BBB breakdown and dysfunction in neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of neurological disorder. Finally, we comment on future approaches and models to better define, at the cellular and molecular level, the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapies for BBB repair to control neurodegeneration.

Introduction

The blood–brain barrier (BBB) is formed by a tightly sealed monolayer of brain endothelial cells, which keeps neurotoxic plasma-derived components, RBCs, leukocytes, and pathogens out of the central nervous system (CNS; Zlokovic, 2011). The capillary length in mouse and human brain is 0.6 and 650 km, respectively, which accounts for >85% of total cerebral blood vessel length, providing the largest endothelial surface area for solute transport exchanges between blood and brain, and vice versa (e.g., ∼120 cm2/g of brain; Zlokovic, 2008; Pardridge, 2015). Endothelium allows free, rapid diffusion of oxygen and carbon dioxide across the BBB. Specialized endothelial transport systems carry energy metabolites, nutrients, and regulatory molecules across the BBB from blood to brain and metabolic waste products and potentially neurotoxic molecules from brain to blood. This includes solute carrier-mediated transport of carbohydrates (e.g., glucose), amino acids, vitamins, hormones, nucleotides, and monocarboxylic acids (e.g., lactate); receptor-mediated transport (RMT) of peptides and proteins; a major facilitator transporter of essential omega-3 (ω-3) fatty acids; ATP-binding cassette active efflux of xenobiotics and drugs; and multiple ion transporters. The BBB transport systems and cellular junctions have been recently reviewed elsewhere (Zhao et al., 2015a).

The mean distance between the BBB and neurons is ∼8 µm, allowing rapid diffusion of molecules across the brain interstitial space from capillaries to neurons, and vice versa (Pardridge, 2015). The BBB controls the composition of neuronal internal milieu, which is essential for proper neuronal and synaptic functioning (Zhao et al., 2015a). The BBB-associated mural cells (pericytes) play a key role in the formation and maintenance of the BBB (Armulik et al., 2010; Bell et al., 2010; Daneman et al., 2010; Sweeney et al., 2016). BBB breakdown has been shown in Alzheimer’s disease (AD; Zlokovic, 2011) and is associated with cerebral blood flow (CBF) reductions and impaired hemodynamic responses (Iadecola, 2013, 2017; Kisler et al., 2017a). Recent imaging and biomarker studies suggest an early BBB breakdown and vascular dysregulation in AD detectable before cognitive decline and/or other brain pathologies (Montine et al., 2014; Montagne et al., 2015, 2016; Snyder et al., 2015; Sweeney et al., 2015; Iturria-Medina et al., 2016; van de Haar et al., 2016a; Kisler et al., 2017a). Neuropathological studies also support early contribution of cerebral vessel disease to AD (Toledo et al., 2013; Arvanitakis et al., 2016).

Here, we briefly summarize key findings from human studies demonstrating BBB breakdown and dysfunction in AD and examine BBB breakdown in transgenic models frequently used to study pathophysiology of AD. We concentrate on animal models carrying major autosomal-dominant AD (ADAD) mutations in human amyloid-β precursor protein (APP) and presenilin 1 (PSEN1) genes (Zhao et al., 2015a), Tau gene, and apolipoprotein E (APOE) ε4 allele, a major genetic risk factor for sporadic, late-onset AD (Verghese et al., 2011; Liao et al., 2017). We also briefly discuss findings in pericyte-deficient models, because pericytes maintain BBB integrity and they degenerate in AD (Sweeney et al., 2016) and AD models (Park et al., 2013b; Sagare et al., 2013). Other models associated with BBB breakdown, such as PGRN (progranulin)-deficient mice modeling loss-of-function mutations in the PGRN gene linked to frontotemporal dementia (Jackman et al., 2013), deficiency in endothelial sphingosine-1-phosphate receptor 1 (Yanagida et al., 2017), and vascular risk factors such as diabetes and hypertension (Girouard and Iadecola, 2006; Iadecola, 2013; Nelson et al., 2016), have been summarized elsewhere.

We focus on CNS capillaries that maintain the largest surface area of the BBB. Additionally, we examine changes in other vascular segments, including arterioles and small arteries, which when disrupted also contribute to a loss of blood-to-brain vascular integrity. We discuss the role of BBB breakdown and dysfunction in the neurodegenerative process, pitfalls in BBB measurements, and how targeting the BBB can influence the course of a neurological disorder. We also suggest future cellular and molecular studies to investigate the underlying mechanisms between BBB breakdown and neurodegeneration as a basis for developing new therapeutic approaches for BBB repair to control neurodegeneration.

BBB breakdown in AD

Recent neuroimaging studies in individuals with mild cognitive impairment (MCI) and early AD have shown BBB breakdown in the hippocampus (Montagne et al., 2015) and several gray and white matter regions (van de Haar et al., 2016a,b, 2017), respectively, before brain atrophy or dementia. These neuroimaging studies used advanced dynamic contrast-enhanced magnetic resonance imaging (MRI) to determine BBB permeability to the contrast agent Gadolinium. Increased CNS cerebral microbleeds reflecting loss of cerebrovascular integrity have also been shown by MRI studies in 25% of individuals with MCI and 45–78% of individuals with early AD before dementia (Brundel et al., 2012; Heringa et al., 2014; Yates et al., 2014; Shams et al., 2015; Poliakova et al., 2016; Shams and Wahlund, 2016).

The BBB breakdown in AD has been confirmed by more than 20 independent postmortem human studies showing brain capillary leakages and perivascular accumulation of blood-derived fibrinogen, thrombin, albumin, immunoglobulin G (IgG) and hemosiderin deposits, pericyte and endothelial degeneration, loss of BBB tight junctions, and RBC extravasation, as recently reviewed (Nelson et al., 2016). An early cerebrovascular disorder (Toledo et al., 2013; Arvanitakis et al., 2016), vascular dysregulation (Iturria-Medina et al., 2016), ischemic vascular damage from comorbidities and vascular risk factors (Iadecola, 2013; Faraco et al., 2016; Nelson et al., 2016), and small vessel disease of the brain (Wardlaw et al., 2013; Snyder et al., 2015; Hachinski, 2016) may introduce additional vascular components contributing to BBB breakdown in AD.

The identification of peripheral macrophages (Hultman et al., 2013) and neutrophils (Zenaro et al., 2015) in the brain in human AD suggests BBB breakdown to circulating leucocytes and their influx into the brain. A novel matrix metalloproteinase radioactive positron emission tomography (PET) ligand was recently used to visualize leukocyte penetration across the BBB and infiltration into the brain in patients with multiple sclerosis (Gerwien et al., 2016). Similar studies, however, have not yet been performed in AD patients, and it remains unclear whether leukocyte infiltration is a cause or a consequence of BBB breakdown.

Multiple studies with [18F]Fluoro-2-deoxy-d-glucose (FDG-PET) in individuals with MCI and early AD showed impaired regional brain uptake of glucose before brain atrophy, neurodegeneration, or conversion to AD, suggesting reduced glucose brain utilization caused by diminished glucose transport across the BBB via endothelial-specific glucose transporter 1 (GLUT1), as recently reviewed (Nelson et al., 2016). 2-Deoxy-d-glucose (2DG) was originally developed by Sokoloff as a surrogate molecule to study brain glucose uptake and utilization (Sokoloff et al., 1977). Similar to glucose, 2DG is transported across the BBB by GLUT1, and after crossing the BBB, it is taken up by different cell types in the brain, including neurons and astrocytes (Cunnane et al., 2011). 2DG is rapidly phosphorylated by intracellular hexokinase (Sols and Crane, 1954) and converted in the brain into 2DG-6-phosphate (2DG-6P; Sokoloff et al., 1977; McDougal et al., 1990). However, unlike glucose-6-phosphate, which is metabolized further in the glycolytic pathway, 2DG-6P is not a substrate for glucose-6-phosphate isomerase and therefore cannot be converted into fructose-6-phosphate, a necessary step to enter the glycolytic pathway or Krebs cycle, as shown by multiple independent studies (Sols and Crane, 1954; Sokoloff et al., 1977; McDougal et al., 1990; Rokka et al., 2017). For example, studies in the mouse brain using enzymatic assays indicated that 1 h after 2DG systemic administration, ∼90% is converted into 2DG-6P and 10% remains as 2DG, with no other significant metabolites found (McDougal et al., 1990). This has been confirmed by another study in the mouse brain using thin-layer chromatography and digital autoradiography, which indicated that after 1 h of [18F]-DG administration, 97% of the [18F]-DG is converted into [18F]-DG-6P (Rokka et al., 2017). Similarly, at longer time points, such as 90 min after [19F]-DG administration to rats, 90% of the [19F]-DG in the brain is converted into [19F]-DG-6P and/or its epimers that are not metabolized further, whereas 10% remains as [19F]-DG (Southworth et al., 2003). Because of minimal glucose-6-phosphatase activity in the brain (Hers and De Duve, 1950; Sokoloff et al., 1977) and low 2DG-6P membrane permeability, 2DG-6P remains trapped in brain cells (Huang and Veech, 1985; Southworth et al., 2003) and is eliminated very slowly from the brain.

P-glycoprotein (Pgp) dysfunction in BBB active efflux transport of xenobiotics and drugs in individuals with early AD has also been shown using verapamil (Pgp ligand)-PET (van Assema et al., 2012; Deo et al., 2014). Implications of BBB breakdown and dysfunction in BBB transport systems for development of brain pathology based on findings in AD models are discussed next.

BBB breakdown in APP transgenic models

Transgenic models expressing mutations in human APP gene linked to early ADAD have been frequently used to study the pathophysiology of AD and/or develop treatments to control AD-related cerebral β-amyloidosis. Here, we examine BBB breakdown in APP transgenic models and its relationship with Alzheimer’s amyloid-β (Aβ) pathology, neurodegeneration, and behavioral deficits (Table 1).
Several independent studies have shown BBB breakdown in APPSw/0 mice harboring the Swedish double APP mutation (KM670/671NL) driven by the hamster prion gene promoter (Hsiao et al., 1996). This mutation increases abnormal cleavage of cellular APP by β-secretase, causing Aβ overproduction. The BBB breakdown has been demonstrated by capillary leakages of blood-derived fibrinogen, IgG, and albumin; BBB leakage of intravenously administrated Evans blue; and immunohistological and electron microscopy studies showing degeneration and loss of brain capillary pericytes, endothelial cells, vascular smooth muscle cells (VSMCs), loss of endothelial tight junction proteins, and cerebral microhemorrhages (Kumar-Singh et al., 2005; Paul et al., 2007; Biron et al., 2011; Park et al., 2013b; Sagare et al., 2013; Table 1). Previous studies have shown that leakage of molecules across the BBB could be caused by a loss and/or misalignment of the tight junction proteins and/or enhanced bulk flow fluid transcytosis across the BBB (Zhao et al., 2015a). Additionally, pericyte degeneration has been shown to lead to BBB disruption at the level of brain capillaries (Armulik et al., 2010; Bell et al., 2010; Daneman et al., 2010). VSMC degeneration is associated with the breakdown of vascular integrity at the level of small arterioles and arteries, often causing microhemorrhages (Holtzman et al., 2000; Bell et al., 2009). Brain endothelial degeneration is typically seen with advanced damage to the BBB at the capillary level (Zlokovic, 2008).

Studies examining the time course between BBB breakdown and other pathologies indicated that BBB breakdown develops early in APPSw/0 mice (at 1, 3, and 6 mo of age; Ujiie et al., 2003; Paul et al., 2007; Sagare et al., 2013) before Aβ deposition, cerebral amyloid angiopathy (CAA), and/or behavioral deficits that develop later (at 7–10, 9–12, and 6–9 mo of age, respectively; Domnitz et al., 2005; Webster et al., 2014). The underlying mechanisms of early BBB disruption in APPSw/0 mice remain elusive but likely involve direct vasculotoxic effects of oligomeric Aβ and/or other APP-mediated toxic effects on vasculature.

The role of BBB breakdown in the development of brain pathologies has been supported by findings showing that loss of pericytes causing an accelerated BBB breakdown also accelerates parenchymal Aβ deposition and CAA and leads to tau pathology and neuronal loss, which is not seen in APPSw/0 mice but has been shown in double-transgenic APPSw/0; Pdgfrβ+/− (platelet-derived growth factor receptor β) mice with accelerated pericyte loss (Sagare et al., 2013).

Aberrant expression of BBB transporters and/or receptors in cerebral microvessels has also been shown in APPSw/0 mice and other APP models. This includes low levels of low-density lipoprotein receptor–related protein 1 (LRP1), a major clearance receptor for Aβ toxin at the BBB (Deane et al., 2004). Its diminished expression in brain capillaries precedes onset of Aβ pathology and behavioral deficits in APPSw/0 mice and triple-transgenic APPSwDI mice carrying three human APP mutations (Swedish, Dutch, and Iowa) under the control of the mouse Thy1 neuronal promoter (Deane et al., 2004). Genetic approaches have demonstrated that increasing or diminishing LRP1 levels in cerebral blood vessels slows down or accelerates Aβ pathology and CAA in APPSw/0 and APPSwDI mice, respectively (Bell et al., 2009; Table 1). Genetic deletion of LRP1 from brain endothelium also accelerates Aβ pathology in 5xFAD mice (Storck et al., 2016) carrying three APP mutations (Swedish, Florida, and London) and two Presenilin 1 human mutations (PSEN1 M146L and PSEN1 L286V; Oakley et al., 2006) causing ADAD (Karch et al., 2014).

Expression of the receptor for advanced glycation end products (RAGE), a major Aβ influx receptor at the BBB, is increased in brain microvessels in APPSw/0 and 5xFAD mice, which accelerates reentry of circulating Aβ into the brain, causing Aβ accumulation, CBF reductions, and a neuroinflammatory response (Deane et al., 2003) and BBB breakdown (Kook et al., 2012), respectively. Blockade of RAGE slows down Aβ pathology and behavioral deficits in PD-hAPP mice expressing a mutant form of human APP encoded by a minigene containing several substitutions from ADAD (V717F, K670M, and N761L) under the control of platelet-derived growth factor B (PDGF-B) chain promoter (Deane et al., 2003; Table 1).

APPSw/0 mice develop an early GLUT1 BBB dysfunction that reduces brain glucose uptake (Niwa et al., 2002). Moreover, diminished GLUT1 expression in brain endothelium leads to BBB breakdown and transcriptionally inhibits LRP1. This accelerates Aβ pathology and leads to secondary neurodegenerative changes, loss of neurons, and brain atrophy, as shown in double-transgenic Slc2a1+/−; APPSw/0 mice with GLUT1 endothelial-specific haploinsufficiency (Winkler et al., 2015). Loss of brain endothelial Pgp efflux transporter also diminishes LRP1 expression at the BBB and leads to brain accumulation of Aβ, as shown in triple-transgenic APPSw/0; mdr1a/b−/− (Pgp-null) mice (Cirrito et al., 2005). Additionally, Pgp endothelial dysfunction diminishes active efflux at the BBB, leading to brain accumulation of potentially neurotoxic xenobiotics such as environmental pollutants, food additives, pesticides, and drugs (Mokgokong et al., 2014).

Recent studies have shown that brain endothelial deficiency in the phosphatidylinositol-binding clathrin assembly (PICALM) protein encoded by the PICALM gene, a highly validated genetic risk factor for human AD (Harold et al., 2009; Lambert et al., 2009; Huang et al., 2017), accelerates Aβ deposition in APPSw/0 mice, consistent with its critical role in regulating LRP1-mediated Aβ internalization at the abluminal side of the BBB and Aβ transcytosis and clearance across the BBB via Rab5- and Rab11-guided vesicular trafficking (Zhao et al., 2015b; Table 1).

Several studies using other APP transgenic models, such as APP V717F, APPSw/I (Swedish, Indiana), APPSwDI, and APPSw/Arc (Swedish, Arctic), and APP mice crossed with PSEN1 ADAD mutants, confirmed BBB breakdown, including fibrinogen, IgG, and albumin perivascular deposits; BBB leakage of Evans blue and contrast imaging agents; microhemorrhages; leukocyte infiltration; loss of tight junctions; and diminished GLUT1 and LRP1 expression at the BBB (Table 1). Collectively, these data provide strong experimental support for the role of BBB breakdown and dysregulated BBB transport in AD pathophysiology.

BBB breakdown in PSEN1 transgenic models

PSEN1 ADAD mutations lead to elevated Aβ production (Tanzi, 2012; Potter et al., 2013; Karch et al., 2014; Elbert et al., 2015), neuronal dysfunction (Lee et al., 2010; Karch and Goate, 2015), and major cerebrovascular pathology, including BBB breakdown; pericyte degeneration; Aβ capillary, arteriolar, and arterial deposits; and decreased BBB glucose uptake, as shown by human postmortem studies (Dermaut et al., 2001; Mann et al., 2001; Armstrong, 2008) and imaging studies in the living human brain (Bateman et al., 2012; Benzinger et al., 2013; Fleisher et al., 2015), respectively. Consistent with these findings, PSEN1-knockout mice (Wen et al., 2005) and mice expressing PSEN1 mutations driven by the neuronal Thy1 promoter (Gama Sosa et al., 2010) develop BBB breakdown and microhemorrhages and loss of BBB integrity and reductions in microvasculature, suggesting loss-of-function vascular phenotype in the absence of CAA and/or other Aβ-related pathology. Vascular and BBB changes are also seen in PSEN1 models crossed with APP mice (Kumar-Singh et al., 2005; Kelly et al., 2015; Table 1).

BBB breakdown in Tau transgenic mice

BBB leakage of Evans blue, IgG perivascular deposits, microhemorrhages, and leukocyte infiltration indicating BBB breakdown have been shown in hTau.P301L mice before significant accumulation of tau pathology (Blair et al., 2015; Table 1) and in the absence of CAA and/or other Aβ pathology. These mice carry a Pro to Leu mutation at codon 301 of the tau gene driven by an inducible Tet-on promoter. In humans, this tau mutation leads to early-onset frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) that is characterized by extensive tau pathology (Lewis et al., 2000). Whether the underlying mechanisms of BBB breakdown involve disrupted tau clearance across the BBB or direct vasculotoxic effects of tau remains unclear at present. Interestingly, Tau P301L mice actually outperform wild-type littermates in behavioral tests within the first 2–3 mo of age (Boekhoorn et al., 2006), before the onset of BBB breakdown, raising the possibility that other pathologies, including BBB breakdown, may contribute to dementia and motor symptoms. Because tau pathology is seen in AD, these findings are relevant to AD dementia as well. Future studies should determine the role of BBB breakdown and tau clearance across the BBB in models of dementias caused by tau pathology.

BBB breakdown in Pdgfrβ-deficient transgenic mice

Pericyte-deficient transgenic mice, including Pdgfrβ+/− mice and PdgfrβF7/F7 mice with disrupted Pdgfrβ signaling, develop an early and progressive BBB breakdown (Bell et al., 2010; Daneman et al., 2010; Nikolakopoulou et al., 2017) and impaired hemodynamic responses (Kisler et al., 2017b) beginning at 1 mo of age. These vascular changes lead to secondary neurodegeneration, loss of cortical and hippocampal neurons, and behavioral deficits at 6–9 mo of age (Table 1). Loss of pericytes in mice with diminished PDGF-BB bioavailability also leads to an early BBB breakdown (Armulik et al., 2010) and calcium deposition in the basal ganglia detectable at 1 yr of age (Keller et al., 2013; Vanlandewijck et al., 2015). Because pericytes degenerate in human AD and other neurodegenerative disorders (Sweeney et al., 2016), these findings support vascular-mediated neurodegeneration independent of Aβ and tau pathology.

BBB breakdown in APOE transgenic models

The apolipoprotein E (APOE) gene is the strongest genetic risk factor for AD (Verghese et al., 2011; Zlokovic, 2013; Liao et al., 2017). One and two APOE ε4 alleles increase risk by ∼3.8- and ∼12-fold, respectively, compared with ε3/ε3 genotype, respectively. The effect of one ε4 allele on AD risk is stronger in females than in males. One copy of APOE ε2 allele decreases risk by ∼0.6-fold relative to ε3/ε3 genotype. Additionally, APOE4 increases the risk of CAA.

APOE exerts its toxic effects on the cerebrovascular system (Zlokovic, 2013) and neurons (Mahley and Huang, 2012) and influences Aβ clearance, amyloid deposition, and tau-related neurodegeneration in an allele-dependent manner (ε4>ε3>ε2; Holtzman et al., 2012; Liao et al., 2017). Despite the fact that APOE has such a strong effect on AD risk, we still lack a comprehensive understanding of how the effects of APOE on the cerebrovascular system and other aspects of its function contribute to AD. We also do not have an effective ApoE-based therapy for AD.

Apoe−/− mice lacking mouse apolipoprotein E (Apoe) develop BBB breakdown, as shown by accumulation of perivascular IgG, fibrinogen, thrombin, and hemosiderin deposits; leakage of Evans blue, different exogenous tracers, or MRI contrast agents; penetration of N-methyl-d-aspartate receptor antibodies; loss of tight junctions; basement membrane degeneration; and loss of perivascular pericytes (Fullerton et al., 2001; Methia et al., 2001; Mulder et al., 2001; Hafezi-Moghadam et al., 2007; Nishitsuji et al., 2011; Bell et al., 2012; Hammer et al., 2014; Soto et al., 2015; Castillo-Gomez et al., 2016; Di Cataldo et al., 2016; Table 2). These studies indicate that Apoe is essential for maintaining BBB integrity.
Studies using transgenic mice with targeted replacement of mouse Apoe with each human APOE isoform (TR-APOE) or mice expressing each human APOE isoform under control of the astrocyte-specific glial fibrillary acidic protein (GFAP) promoter on an Apoe-null background, have shown that expression of APOE4, but not APOE2 and APOE3, leads to BBB breakdown (Nishitsuji et al., 2011; Bell et al., 2012) and cerebral microhemorrhages (Cacciottolo et al., 2016; Table 2). Loss of endothelial GLUT1 expression and increased expression of RAGE have also been shown in TR-APOE4 mice, but not TR-APOE3 or TR-APOE2 mice (Alata et al., 2015). Studies in human APOE4 carriers compared with noncarriers have also demonstrated a more pronounced BBB breakdown and pericyte degeneration (Salloway et al., 2002; Zipser et al., 2007; Hultman et al., 2013; Zonneveld et al., 2014; Halliday et al., 2016), diminished regional BBB uptake of glucose (Ossenkoppele et al., 2013; Protas et al., 2013), and early neurovascular dysfunction (Reiman et al., 2004; Sheline et al., 2010; Thambisetty et al., 2010; Hajjar et al., 2015; Suri et al., 2015).

Genetic ablation, siRNA silencing, and pharmacological studies in transgenic APOE4 mice revealed that activation of the proinflammatory cyclophilin A (CypA)–matrix metalloproteinase 9 (MMP-9) pathway in pericytes leads to degradation of tight junction and basement membrane proteins causing BBB breakdown (Bell et al., 2012). Interestingly, neuropathological findings in AD APOE4 carriers compared with noncarriers also demonstrate elevated levels of CypA and MMP-9 in brain endothelium and pericytes that correlate with elevated IgG and fibrinogen capillary leakages, suggesting activation of the CypA-MMP-9 BBB degrading pathway (Halliday et al., 2016). Cerebrospinal fluid analysis in APOE4 nonsymptomatic carriers compared with noncarriers confirmed that activation of the CypA–MMP9 pathway correlates with BBB breakdown (Halliday et al., 2013), which has been also corroborated by tissue CypA mRNA analysis (Conejero-Goldberg et al., 2014).

An early and progressive BBB breakdown detectable in TR-APOE4 and GFAP-APOE4 mice between 2 and 6 wk of age precedes changes in sensory-evoked neuronal functioning, loss of neuritic density, and loss of pre- and postsynaptic proteins that develop at 4 mo of age (Bell et al., 2012). Importantly, pharmacologic inhibition of the CypA–MMP-9 BBB pathway in addition to repairing the BBB also slowed down and reversed neurodegenerative changes in APOE4 and Apoe−/− mice. Similarly, genetic inhibition of the CypA–MMP-9 pathway at the BBB reversed neurodegenerative changes in Apoe−/− mice (Bell et al., 2012). Because Apoe−/− (Raber et al., 1998; Bell et al., 2012; Lane-Donovan et al., 2016) and APOE4 transgenic mice (Bell et al., 2012; Salomon-Zimri et al., 2014, 2015; Liu et al., 2015) develop behavioral deficits at 4–6 mo of age after BBB breakdown, collectively, these findings suggest that BBB breakdown (Table 2) not only contributes to neuronal changes in these models but also is an important therapeutic target.

Several studies have established that human APOE isoforms differentially regulate brain Aβ clearance (Castellano et al., 2011), as reviewed elsewhere (Verghese et al., 2011; Liao et al., 2017). Consistent with these findings, APOE isoforms differentially regulate Aβ clearance across the BBB (Deane et al., 2008; Zhao et al., 2015b). Studies in animal models have shown that APOE3 and APOE2 mediate Aβ clearance across the BBB via LRP1, whereas APOE4 preferentially binds to very-low-density lipoprotein receptor (VLDR) at the mouse BBB, which clears ligands across the BBB at much slower rate than LRP1, contributing to brain accumulation of Aβ (Deane et al., 2008).

Potential pitfalls in BBB permeability measurements

High-resolution confocal microscopy analysis and multiphoton microscopy imaging of various endogenous and exogenous tracers, studies using molecular biomarkers of BBB cellular breakdown and/or dysfunction, electron microscopy studies, and MRI studies strongly support BBB breakdown in animal models of AD and Apoe−/− and APOE4 transgenic mice (Tables 1 and 2). Some studies, however, did not detect BBB breakdown in Apoe−/− and TR-APOE4 mice using exogenous circulating antibodies (e.g., IgG and anti–β-secretase 1 [BACE1]) but showed significant brain uptake of the bispecific therapeutic anti–transferrin receptor–BACE1 antibody, which uses the Trf receptor to cross the BBB (Bien-Ly et al., 2015). Interestingly, this study also did not detect BBB breakdown in a superoxide dismutase-1 SOD1G93A model of amyotrophic lateral sclerosis (ALS) using control IgG and anti–BACE1 antibodies (Bien-Ly et al., 2015). In contrast, multiple independent studies in SOD1G93A mice and other SOD1 ALS mutants reported an early BBB breakdown using different techniques and approaches (Garbuzova-Davis et al., 2007a,b; Zhong et al., 2008, 2009; Nicaise et al., 2009; Miyazaki et al., 2011; Winkler et al., 2014). Here, we briefly discuss potential reasons for discrepancy between different studies and possible factors that could interfere with interpretation of BBB measurements in animal models.

In brief, the use of systemically administered exogenous macromolecules such as nonimmune antibodies to determine BBB permeability requires extensive vascular perfusion of the brain with cold saline at the end of experiment to eliminate antibodies from cerebral blood vessels (Bien-Ly et al., 2015). However, this perfusion step can also remove tracers from the brain, particularly nonfixable ones such as exogenous nonimmune IgG, which tends to underestimate brain uptake values. This could be particularly critical in models with focal and/or rather discrete BBB changes, when tracer concentration is determined in brain homogenates or lysates. To overcome this problem, some studies used tissue-fixable tracers, such as Cadaverine-Alexa Fluor 555 (Armulik et al., 2010; Bell et al., 2012) or lysine fixable dextrans (Ben-Zvi et al., 2014), which after crossing the disrupted BBB remain bound to brain tissue and therefore are easily detectable by either histological or biochemical analysis.

Besides technical challenges, BBB breakdown in models of neurodegenerative disorders (Zlokovic, 2011) and in humans with these disorders such as AD (Montagne et al., 2016; Nelson et al., 2016) typically starts focally (Montagne et al., 2015) and then spreads throughout several gray and white matter regions (van de Haar et al., 2016a,b, 2017). In contrast, BBB breakdown in models of neuroinflammation, such as experimental allergic encephalitis, is more widespread and robust (Wang et al., 2016; Shaw et al., 2017), similar to multiple sclerosis in humans, where BBB breakdown develops more rapidly and is typically an order of magnitude greater than in neurodegenerative disorders such as AD (Montagne et al., 2016). Thus, experimental approaches that rely solely on biochemical analysis of the exogenous tracer’s concentration in brain lysates without additionally using tissue imaging analysis might run the risk of missing subtle changes in BBB integrity around brain capillaries first affected by the disease process, which are otherwise detectable by high-resolution confocal or multiphoton microscopy analysis (Paul et al., 2007; Bell et al., 2010, 2012).

It is not completely unexpected, therefore, that studies using systemically administered radiolabeled tracers (e.g., dextran and albumin) and assaying their concentration in different CNS tissue lysates were able to readily detect BBB permeability increases in models of neuroinflammation, but not in models of neurodegenerative disorders (Bien-Ly et al., 2015). Because multiple independent studies by different groups showed BBB breakdown in models of neurodegeneration using imaging techniques (Tables 1 and 2), the question persists whether radiotracer methods alone are sensitive enough to detect focal and less pronounced BBB changes. A recent neuroimaging study in individuals with MCI also suggests that even within a single brain region in humans, as for example in the hippocampus, some subregions may have intact BBB, such as CA3, whereas others such as CA1 and dentate gyrus show BBB breakdown (Montagne et al., 2015). Combining different methods and approaches is therefore highly recommended to ascertain whether given animal models develop BBB breakdown.

Targeting BBB to control neurodegeneration…..

Leave a Reply